Efficacy and Tolerability of Enstilar® in Daily Practice
Launched by LEO PHARMA · Aug 23, 2016
Trial Information
Current as of May 21, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • ≥ 18 years of age
- • Psoriasis vulgaris
- • Lesions on trunk and/or extremities of at least mild severity
- • Treatment with Enstilar® planned
- • Signed informed consent to participate
- Exclusion Criteria:
- • Enrolled in any interventional clinical trial
- • Ongoing or recent treatment with any systemic psoriasis
- • Ongoing or recent treatment with UV-therapy
- • Ongoing or previous treatment with Enstilar®
- • Psoriasis of scalp only
- • Other forms of psoriasis, e.g. erythrodermic or pustular psoriasis
- • More than 30% of surface area affected by psoriasis
- • Any contraindications or known allergies to Enstilar® or its ingredients
- • Incapacitated patients under institutionalized care
About Leo Pharma
LEO Pharma is a global pharmaceutical company dedicated to developing innovative therapies for dermatological and critical care conditions. With a strong focus on research and development, LEO Pharma aims to improve the lives of patients through advanced treatments and a commitment to high-quality standards. The company collaborates with healthcare professionals and stakeholders to address unmet medical needs and drive scientific progress in the field. Through its clinical trials, LEO Pharma seeks to enhance therapeutic options and provide effective solutions for patients suffering from skin diseases and other related health issues.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Kiel, , Germany
Patients applied
Trial Officials
Sascha Gerdes, Dr.med.
Principal Investigator
Clinic for Dermatology, Venereology and Allergy, University Clinic Schleswig-Holstein, Campus Kiel
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials